Omega Therapeutics (NASDAQ:OMGA) Stock, Quote.Headers.trade-ideas

Omega Therapeutics

Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.

5 Auto Taxi Projects Set To Challenge Uber And Lyft

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

CTSH

FTNT

ICHR

OMGA

PGNY

UBER

Uber To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Wednesday

Biotech

Earnings

Earnings Misses

Penny Stocks

Trading Ideas

General

CYTK

Omega Therapeutics, Inc. (NASDAQ: OMGA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.

Omega Therapeutics, Inc. Reports Q1 Loss, Tops Revenue Estimates

Small Cap

Intraday Update

Movers

AIMD

ALLO

ANGO

APLT

ATXI

AXGN

BNZI

CISO

CPRX

CYCC

DRMA

ELAN

EXAI

IMCR

Intelligent Bio Solutions Inc. - Common Stock

INBS

KORE

KRUS

LSDI

NEXI

PNST

PTON

PYPD

RCAC

SABS

SMFL

SWVL

TBPH

VERB

VYGR

Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Omega Therapeutics Inc

Stifel analyst Shlomo Rosenbaum maintains Iron Mountain (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRM#NYSE">IRM</a>) with a Buy and raises the price target from $117 to $140.

Stifel Maintains Buy on Iron Mountain, Raises Price Target to $140

KRON

Kronos Bio Highlights Preclinical Data At AACR Symposium Supporting Istisociclib Clinical Evaluation In Advanced Ovarian Cancer, Showing Efficacy In Platinum And PARP-Inhibitor Resistant Models

Management

QTWO

Q2 Appoints Jonathan Price As CFO

Citigroup analyst Nelson Cheung downgrades So-Young Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SY#NASDAQ">SY</a>) from Buy to Neutral and lowers the price target from $1.5 to $0.8.

Downgrades

Citigroup Downgrades So-Young Intl to Neutral, Lowers Price Target to $0.8

OTRK

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Stifel analyst Tom Roderick maintains Intapp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTA#NASDAQ">INTA</a>) with a Buy and raises the price target from $45 to $60.

INTA

Stifel Maintains Buy on Intapp, Raises Price Target to $60

Stifel analyst Thomas Stephan maintains Bausch &amp; Lomb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) with a Hold and raises the price target from $16 to $19.

BLCO

Stifel Maintains Hold on Bausch & Lomb, Raises Price Target to $19

Citigroup analyst Filippo Falorni upgrades Keurig Dr Pepper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) from Neutral to Buy and raises the price target from $36 to $43.

Upgrades

Citigroup Upgrades Keurig Dr Pepper to Buy, Raises Price Target to $43

Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) expanded its digital bank <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40974376/nasdaq-expands-digital-bank-fintech-presence-in-latin-america" rel="noreferrer noopener">financial technology operations in Latin America</a>.
Notably, the company agreed to supply Nubank with its AxiomSL regulatory reporting solution. Nubank is a digital bank that serves over 100 million customers across Brazil, Mexico, and Colombia.
The agreement strengthens Nasdaq&#8217;s partnership with Nubank, extending support from treasury operations to regulatory reporting in Colombia.
The company underscores the growing demand for third-party financial technology solutions in Latin America, driven by the rapid expansion of digital banking and the need for quick market entry for new products and services.
Nasdaq serves over 50 banking and payment services clients in Latin America, including a mix of digital and traditional banks, local and regional players, and tier-one global banks.
Ed Probst, Senior Vice President, Regulatory Technology at Nasdaq said, &#8220;Digital banking services in Latin America are experiencing a period of extraordinary development, with online marketplaces, open banking and innovative technology combining to empower a new generation of consumers.&#8221;
&#8220;Nasdaq&#8217;s technology is helping to underpin the maturation of the industry, with proven regulatory solutions substantially reducing time to market and providing a competitive advantage in such a fast-paced industry.&#8221;
This month, Nasdaq unveiled a new leadership structure, including an appointment for its Financial Crime Management Technology business, to strengthen its <a target="_blank" href="https://www.benzinga.com//node/40746798" rel="noreferrer noopener">momentum and support continued growth.</a>
Investors can gain exposure to the stock via&nbsp;Listed Funds Trust Horizon Kinetics Blockchain Development ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCDF#NYSE">BCDF</a>) and iShares U.S. Broker-Dealers &amp; Securities Exchanges ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAI#NYSE">IAI</a>)
Price Action: NDAQ shares are down 0.08% at $74.23 premarket at the last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40715673/ipo-rebound-and-fintech-growth-potential-is-helping-nasdaq-analyst-double-upgrades-stock" target="_blank" rel="noreferrer noopener">IPO Rebound And FinTech Growth Potential Is Helping Nasdaq: Analyst Double Upgrades Stock</a></li>
</ul>

Equities

Large Cap

Contracts

Listed Funds Trust Horizon Kinetics Blockchain Development ETF

BCDF

iShares Dow Jones US Broker Dealers Index Fund

NDAQ

Nasdaq's AxiomSL Solution Powers Digital Banking, Boosts Presence In Latin America

INTC

QCOM

In Response To Speculation That Qualcomm Is Approaching Intel About A Possible Takeover, Industry Sources In Taiwan Believe The Merger Would Be Disastrous Since It Undervalues Intel While Exaggerating Qualcomm's Capabilities. -DigiTimes

General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) CEO Mary Barra on Sunday reiterated the company&#8217;s aim to sell <a href="https://www.benzinga.com/news/24/09/40975105/general-motors-to-lay-off-about-1700-employees-ahead-of-chevrolet-malibu-phase-out-and-re-tooling-fo">only electric light-duty vehicles</a> by 2035 despite slowing demand for EVs. 
What Happened: &#8220;Our workforce is quite young. Most of our technical talent has been with the company for less than five years and so I would say about 40%. They are joining because they want to be a part of a company that is going to change and lead in the move to electric vehicles,&#8221; Barra said in an <a href="https://www.youtube.com/watch?v=1_qAM1e0E9k">interview</a> with CBS News.
Talking about the ongoing slowdown in EV demand, Barra said, &#8220;I don&#8217;t think we ever thought it was going to be linear.&#8221;
Why It Matters: In the second quarter, GM <a href="https://www.benzinga.com/news/24/07/39612749/60-000-cadillac-lyriq-drives-gms-q2-ev-sales-after-bolt-is-discontinued">sold only 21,930 EVs</a> in the U.S. despite having seven EV models in its lineup. Ford, meanwhile, sold 21,930 units of<a href="https://www.benzinga.com/news/24/07/39630731/mustang-mach-e-drives-fords-q2-ev-sales-ahead-of-gm-but-its-still-just-a-fraction-of-elon-musks-tesl"> just three EV models</a>. 
EV giant Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) sold 164,264 EVs in the period, according to Kelley Blue Book estimates, with the Model Y alone accounting for 101,301 sales. 
Despite having a higher number of EVs in its lineup than even Tesla, GM is looking to add more, including the all-electric Cadillac Escalade IQ starting at around $130,000. The company is also planning to start the production of its next-generation Chevrolet Bolt EV next year. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40975105/general-motors-to-lay-off-about-1700-employees-ahead-of-chevrolet-malibu-phase-out-and-re-tooling-fo">General Motors To Lay Off About 1700 Employees Ahead Of Chevrolet Malibu Phase-Out And Re-Tooling For EV Production</a></li>
</ul>
Photo by Fortune Live Media on Flickr

Tech

TSLA

GM CEO Mary Barra Reiterates Goal Of Selling Only Electric Light-Duty Vehicles By 2035 Despite EV Demand Slowdown, Says Never Expected It To Be 'Linear'

Cantor Fitzgerald analyst Louise Chen reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Overweight and maintains $215 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target

WIIM

ELAB

Elevai Labs shares are trading lower after the company announced the pricing of an $8.0 million public offering.

Vroom shares are trading higher after the company released its long-term strategic plan.

Elevai Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>)&nbsp;("Elevai" or the "Company"), a pioneering force in medical aesthetics, today announced that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold. &nbsp;
The offering is comprised of 28,571,425 shares of the Company's common stock (or pre-funded warrants in lieu of shares of common stock). Each share of common stock or pre-funded warrant will be sold with one Series A Warrant to purchase one share of common stock at an exercise price of $0.38 per share (the "Series A Warrants") and one Series B Warrant to purchase one share of common stock at an exercise price of $0.38 per share or, pursuant to an alternative cashless exercise option, three shares of common stock (the "Series B Warrants" and, together with the Series A Warrants, the "Warrants").&nbsp;The Series A Warrants will be exercisable beginning on the date of completion of the requisite waiting period following the filing of the Information Statement related to the approval by the stockholders of the Company (the "Initial Exercise Date" or "Effective Shareholder Approval Date") of the issuance of shares upon exercise of the Warrants, among other things (the "Shareholder Approval"). The Series B Warrants will be exercisable beginning on the Effective Shareholder Approval Date. The Series A Warrants will expire on the five-year anniversary of the Initial Exercise Date and the Series B Warrants will expire on the two and one-half-year anniversary of the Initial Exercise Date.
The purchase price of each share of common stock and accompanying Warrants is $0.28, and the purchase price of each pre-funded warrant and accompanying Warrants will be equal to such price minus $0.0001.
The Company intends to use the net proceeds from this offering for general corporate purposes, including working capital and investments. This offering is expected to close on or about September 24, 2024, subject to satisfaction of customary closing conditions.
Univest Securities, LLC&nbsp;is acting as sole placement agent for the offering.

Offerings

Elevai Labs Inc. Announces Pricing Of $8M Public Offering Of 28,571,425 Shares Of Common Stock (Or Pre-Funded Warrants In Lieu Of Shares Of Common Stock). Each Share Of Common Stock Or Pre-Funded Warrant Will Be Sold With One Series A Warrant To Purchase One Share Of Common Stock At An Exercise Price Of $0.38/Share

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Overweight and maintains $107 price target.

VERA

Cantor Fitzgerald Reiterates Overweight on Vera Therapeutics, Maintains $107 Price Target

Raymond James analyst Brian Gesuale downgrades Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) from Outperform to Market Perform.

PLTR

Raymond James Downgrades Palantir Technologies to Market Perform

Consumers are turning more frequently to their 401(k) accounts to pay down <a href="https://www.benzinga.com/insights/news/24/09/40960923/heres-how-much-you-would-have-made-owning-mastercard-stock-in-the-last-10-years">their credit cards</a> as they face higher prices for essentials such as food, gas and electricity, according to a financial planner.
Total credit-card debt in the U.S. reached $1.34 trillion as of June, Federal Reserve data <a href="https://www.federalreserve.gov/releases/g19/20240909/">showed</a>. In May, credit card balances for consumers between 43 and 58 years old <a href="https://www.benzinga.com/general/education/24/05/39059618/this-generation-has-more-credit-card-debt-than-millennials-and-gen-z-5-tips-on-how-to-crawl-out">averaged $9,123</a>.
&#8220;People are facing rising prices and while the rate of inflation has decreased, there is still inflation,&#8221; said Bobbi Rebell, a certified financial planner and finance expert at CardRates.com.
&#8220;Therefore, prices are still high, even though they're not going up as quickly. Life is expensive! People are struggling because they're paying more for everyday expenses like groceries.&#8221;
Read Also: <a href="https://www.benzinga.com/news/24/07/39827834/why-capital-one-stock-is-climbing">Why Capital One Stock Is Climbing</a>
Turning to 401(k)s to pay those balances has also risen because the government has made it easier to access some money from a 401(k) without penalties, she said.
&#8220;Also, that's where the money is! Because many employers have auto enrollment and employees must opt out, people have more money in their 401(k) account,&#8221; she said.
&#8220;At least with a 401(k) you are paying yourself interest and the rate is usually more affordable than the interest rate of a credit card.&#8221;
Major drawbacks to using a 401(k) to pay down credit cards is that consumers must pay back what they take out before leaving the job that gave them the 401(k). They are also using funds that are meant to be spent in retirement, she said.
&#8220;You are borrowing money from your future.&#8221;
Price Action: Credit card companies fell slightly on Friday.
<ul>
<li>Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) slipped 0.16% to $284.77.</li>
<li>Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) dropped 0.05% to $493.30.</li>
<li>Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) fell 0.99% to $142.49</li>
<li>Capital One Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) declined 0.52% to $152.25.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39847159/analyst-expects-discover-financial-to-further-narrow-fy24-guidance-this-year-detail">Analyst Expects Discover Financial To Further Narrow FY24 Guidance This Year: Detail</a></li>
</ul>
Photo: Shutterstock

Government

Education

Federal Reserve

Consumers Turn To 401(k)s To Pay Down Credit Cards: 'Life Is Expensive'

Raymond James analyst Patrick O'Shaughnessy downgrades Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) from Market Perform to Underperform.

Raymond James Downgrades Moodys to Underperform

Events

COHR

Coherent To Demonstrate 1.6T-DR8 And 800G-DR4 Transceivers At ECOC 2024

Keay Nakae, an analyst from Chardan Capital, reiterated the Buy rating on Omega Therapeutics (OMGA – Research Report). The associated price target ...

Buy Rating Affirmed for Omega Therapeutics Amid Strong Financials and Promising OTX-2002 Clinical Trials

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fresenius Medical Care AG & Co. KGaA (GB:0H9X – Rese...

Analysts' Top Healthcare Picks: Fresenius Medical Care AG & Co. KGaA (GB:0H9X), Omega Therapeutics (OMGA)

Novo Nordisk, Flagship to develop next-generation obesity drugs

Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Omega Therapeutics (OMGA – Research Report), retaining the price target of $12.0...

Buy Rating Reaffirmed for Omega Therapeutics on Strong Clinical and Financial Performance

Stocks with more than 10% short interest - Finviz Screener

Goldman Sachs raises obesity drug market estimate to $130B

Omega Therapeutics (OMGA) just unveiled an update. Kaan Certel, Ph.D., with over two decades of experience in the biopharmaceutical sector, has bee...

Omega Therapeutics Appoints New Chief Business Officer

Raymond James starts Omega at outperform, cites platform

Omega Therapeutics GAAP EPS of -$0.30, revenue of $2.13M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Omega Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/omga-stock-quote/">OMGA</a>) just reported results for the second quarter of 2024.<ul><li>Omega Therapeutics reported earnings per share of -30 cents. This was above the analyst estimate for EPS of -36 cents.</li><li>The company reported revenue of $2.13 million.</li><li>This was 124.63% better than the analyst estimate for revenue of $950,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/omga-stock-earnings-omega-therapeutics-for-q2-of-2024/">OMGA Stock Earnings: Omega Therapeutics Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OMGA Stock Earnings: Omega Therapeutics Beats EPS, Beats Revenue for Q2 2024

ALPN

AMCX

AMGN

ANVS

BHVN

BIRD

BLNK

DNLI

FTCI

FUBO

GPCR

GRPN

IRBT

LESL

LPSN

MAXN

MCRB

MGNX

MRNA

NARI

NONOF

NRBO

NVAX

PACB

PETS

PHUN

PLUG

PRME

PROK

RDDT

RDFN

RENT

RHTX

RIVN

RXRX

RYTM

SANA

SAVE

SHOT

SPCE

SPWR

TRUP

VKTX

VRCA

VSCO

VTVT

VUZI

VXRT

XPOF

Press Releases

Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer

Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors

Alltrna Announces Updates to Its Board of Directors

Analog Devices and Flagship Pioneering Announce Strategic Partnership to Accelerate the Development of a Fully Digitized Biological World

GSK and Flagship Pioneering partner to discover novel medicines and vaccines

Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner

Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research

"Game-Changing Biotech Companies Making Waves: INBS, PMVP, TPST, OMGA, MRSN"

Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications

APRE

ARQL

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Omega Therapeutics

Omega Therapeutics (OMGA) Forecast

Omega Therapeutics (NASDAQ:OMGA) Stock, Quote.Headers.trade-ideas